Prana says PBT2 improves memory, cognition in Alzheimer's animal study

By Elaine Rigoli

Tampa, Fla., July 19 - Prana Biotechnology Ltd. presented data Wednesday on Alzheimer's disease demonstrating that in mouse models, PBT2 improved memory performance within five days of oral dosing; rapidly reduced the levels of soluble beta-amyloid (Abeta) in the brain; and restored normal function to Abeta-impaired synapses.

The company said recent studies suggest that PBT2 could quickly and significantly improve spatial memory - an important barometer of cognitive function - in seven-month-old transgenic amyloid mice, which are a model for Alzheimer's disease.

In addition, the company referenced a study performed on 15-month-old transgenic Alzheimer's mice treated with 30 mg/kg PBT2, which showed the drug reduced soluble Abeta40 and Abeta42 levels by 60% within 24 hours of oral PBT2 administration.

This data is compelling because it shows that PBT2 may facilitate the clearance of Abeta from the brain or prevent its production and improve cognition, officials noted.

Prana Biotechnology is located in Melbourne, Australia.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.